Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of neoadjuvant trastuzumab, pertuzumab and chemotherapy chosen by the investigators and identify the molecular characterization and subtypes in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Phase:
NA
Details
Lead Sponsor:
Shandong Cancer Hospital and Institute
Treatments:
Drug Therapy Long-Term Synaptic Depression Mastectomy pertuzumab Trastuzumab